Concepedia

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Peter A. Riedell, Hemant S. Murthy, Phoebe Joy Ho, Joseph Maakaron, Edmund K. Waller, Farrukh T. Awan, Paul Shaughnessy,

Blood · 2022 · 53 citations · 0 references

Concepts

Life SciencesImmunologyOncologyCancer ImmunologyGenome EditingImmunotherapyAntitumor T Cell ResponsesCancer ImmunotherapyCrispr-cas SystemsCytotoxic T Lymphocyte ResponsesLymphoid NeoplasmsT Cell ActivationAllogeneic Car T-cell TherapyCar T Cell TrialsDose-escalation DesignsHematologic Malignancy Car T-cell TherapyRelapsed Diffuse Large B-cell LymphomaT Cell Receptor TherapyT Cell-based Immunotherapy